Methods and compositions for oral administration of exenatide
This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.
1. A method for slowing the progression and/or ameliorating the symptoms of diabetes mellitus in a subject, comprising administering orally to said subject a pharmaceutical composition comprising an exenatide having at least 95% identity to HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO: 1), wherein the exenatide has glucagon-like peptide (GLP-1) agonist activity, a protease inhibitor selected from Soybean Trypsin Inhibitor (SBTI) and aprotinin, EDTA, and an omega-3 fatty acid, thereby slowing the progression and/or ameliorating the symptoms of diabetes mellitus, wherein the composition does not comprise both SBTI and aprotinin.
2. The method of claim 1 , wherein said omega-3 fatty acid is derived from fish oil.
3. The method of claim 1 , wherein said protease inhibitor is soybean trypsin inhibitor (SBTI).
4. The method of claim 1 , wherein said pharmaceutical composition further comprises a coating that inhibits digestion of said composition in a stomach of a subject.
5. The method of claim 4 , wherein said coating is an enteric coating.
6. The method of claim 1 , wherein said pharmaceutical composition further comprises a gelatin coating.
7. The method of claim 1 , wherein said protease inhibitor is aprotinin.
8. The method of claim 1 , wherein the sequence of said exenatide is identical to SEQ ID NO: 1.
9. The method of claim 1 , wherein said omega-3 fatty acid is provided in the form of a fish oil.
10. The method of claim 1 , wherein the progression of diabetes mellitus is slowed in the subject.
11. The method of claim 1 , wherein the symptoms of diabetes mellitus are ameliorated in the subject.